|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Defects of the insulin receptor substrate (IRS) system in human metabolic disorders显示文摘 | SESTI G FEDIR1CI M HR1BAL M L | 2001 | FASEB J2001，15，： | 1 |
| 2 | Effects of growth hormone and insulin- like growth factor - 1 on cardiac hypertrophy of hypertensive patients显示文摘 | Sesti G Sciaequa A Scozzafava A | 2007 | Hypertensions2007，25，2： | 1 |
| 3 | A functional variant of the dimethylarginine dimethylaminohydrolase-2 gene is associated with chronic kidney disease显示文摘 | SESTI G MANNINO GC DE LORENZO C | 2013 | Atherosclerosis2013，231，1： | 1 |
| 4 | 血清碱性磷酸酶对未治疗的高血压患者的内皮依赖性血管舒张的不良影响显示文摘组织非特异性碱性磷酸酶是一般人群和肾或心血管病患者总死亡率及心血管死亡率的强有力预测因子。该研究纳入未经治疗的高血压患者500例,按照血清碱性磷酸酶三分位分组,分析血清碱性磷酸酶水平和血管内皮功能(通过应变仪体积描记法评估)可能存在的关联。结果:血管对乙酰胆碱的最大反应与碱性磷酸酶水平呈负相关(r=一0.55,P〈0.01),该相关性独立于人口和传统危险因素,如体质量指数,估算的肾小球滤过率,血清磷和钙,C反应蛋白和蛋白尿。 | 刘莉 叶鹏 Perticone F Perticone M Maio R Sciacqua A Andreucci M Tripepi G Corrao S Mallamaci F Sesti G Zoccali C | 2015 | 中华高血压杂志2015，23，8： | 1 |
| 5 | Effects of growth hormone and insulin-like growth factor-1 on cardiac hypertrophy of hypertensive patients显示文摘 | Sciacqua A Scozzafava A | 2007 | Hypertension2007，25，： | 1 |
| 6 | Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a26-week randomised, parallel-group, multinational, open-label trial (LEAD-6) 显示文摘 | Buse J B Rosenstock J Sesti G | 2009 | Lancet2009，374，9683： | 1 |
| 7 | Defects of the insulin receptor substrate (IRS) system in human metabolic disorders显示文摘 | Sesti G Federici M Hribal ML | 2001 | FASEB J2001，15，12： | 1 |
| 8 | Liraglutide once a day versus exenatide twice a day for type 2 diabetes:a 26-week randomised,parallel-group,multinational,open-label trial(LEAD-6)显示文摘 | Buse JB Rosenstock J Sesti G | 2009 | Lancet2009，374，9683： | 1 |
| 9 | A polymorphism at IGF1 lo- cus is associated with carotid intima media thickness and endotheli- urn-dependent vasodilatation 显示文摘 | Sesti G Marmino GC Andreozzi F | 2014 | Atherosclerosis2014，232，1： | 1 |
| 10 | Liraglutide once a day versus exenatide twice a day for type 2 diabetes:a 26-week randomized, parallel-group,multinational, open-label trial LEAD-6 显示文摘 | Buse J Rosenstock J Sesti G | 2009 | J Lancet2009，374，9683： | 1 |
| 11 | High circulating irisin levels are associated with insulin resistance and vascular atherosclerosis in a cohort of nondiabetic adult subjects显示文摘 | Sesti G Andreozzi F Fiorentino TV | 2014 | Acta Diabetol2014，51，5： | 1 |
| 12 | Defects of the insulin receptor substrate (IRS) system in human metabolic disorders显示文摘 | Sesti G Federici M Hribal ML | 2001 | FASEB J2001，15，12： | 1 |
| 13 | Molecular mechanism of insulin resistance in type 2 diabetes mellitus : role of the insulin receptor varian 显示文摘 | Sesti G Federici M Uauro D | 2001 | Diabetes Metab Res Rev2001，17，： | 1 |
| 14 | Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6) 显示文摘 | BUSE JB ROSENSTOCK J SESTI G | 2009 | Lancet2009，374，9683： | 1 |
| 15 | Liraglutide once a day versue exenatide twice a day for type 2 diabetes: a 26-week randomized, parallel-group, multinational, open-label trail ( LEAD-6 ) 显示文摘 | Buse J Rosenstoek J Sesti G | 2009 | Lancet2009，374，： | 1 |
| 16 | LEAD-6 Study Group: Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial ( LEAD-6 ) 显示文摘 | Buse JB Rosenstock J Sesti G | 2009 | Lancet2009，374，： | 1 |
| 17 | Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinati-onal, open-label trial ( LEAD-6) 显示文摘 | Buse JB Rosenstock J Sesti G | 2009 | Lancet2009，374，9683： | 1 |
| 18 | Liraglutide once a day versus exenatide twice a day for type 2 diabetes:a 26-week randomised, parallel-group, multinational,open-label trial (LEAD-6) 显示文摘 | Buse JB Rosenstock J Sesti G | 2009 | lancet2009，374，9683： | 1 |
| 19 | Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial(LEAD-6)显示文摘 | Buse JB Rosenstock J Sesti G | 2009 | Lancet2009，374，9683： | 1 |
| 20 | Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week radomised, paral- lel-group, multinational, open-label trial (LEAD-6)显示文摘 | Buse JB Rosenstock J Sesti G | 2009 | Lancet2009，374，： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员